Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | ELAC2 |
| Gene Name: | ELAC2 |
| Protein Full Name: | Zinc phosphodiesterase ELAC protein 2 |
| Alias: | ElaC (E. coli) homolog 2; ElaC 2; ElaC homolog 2; ElaC homolog 2 (E. coli); ElaC homolog protein 2; ELC2; FLJ10530; Hereditary prostate cancer; Heredity prostate cancer 2; Heredity prostate cancer protein 2; HPC2; Prostate cancer susceptibility protein; Ribonuclease Z 2; RNase Z 2; RNZ2; TRNA 3 endonuclease 2; TRNase Z (long form); TRNase Z 2; Zinc phosphodiesterase ELAC 2; Zinc phosphodiesterase ELAC protein 2: Ribonuclease Z 2: tRNase Z 2: tRNA 3 endonuclease 2: ElaC homolog protein 2: Heredity prostate cancer protein 2: Putative prostate cancer susceptibility protein HPC2/ELAC2: Zinc phosphodiesterase ELAC protein 2: Ribonuclease Z 2: tRNase Z 2: tRNA 3 endonuclease 2: ElaC homolog protein 2: Heredity prostate cancer protein 2 |
| Mass (Da): | 92219 |
| Number AA: | 826 |
| UniProt ID: | Q9BQ52 |
| Locus ID: | 60528 |
| COSMIC ID: | ELAC2 |
| Gene location on chromosome: | 17p11.2 |
| Cancer protein type: | OP |
| Effect of cancer mutation on protein: | GAIN |
| Effect of active protein on cancer: | PROMOTES |
| Number of cancer specimens: | 19626 |
| Percent of cancer specimens with mutations: | 0.54 |
| Mutations observed as inherited: | Hereditary prostate cancer |
| Normal role description: | ELAC2 is a zinc-phosphodiesterase that exhibits some tRNA 3'-processing endonuclease activity as a ribonuclease. It also interacts with Smad2. ELAC2's downregulation can suppress TGF-beta-induced growth factor arrest, thereby stopping a tumour suppressor pathway. Mutations in this gene are associated with prostate cancer. |